Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 9
2004 6
2005 3
2006 1
2007 1
2008 3
2009 6
2010 3
2011 3
2012 2
2013 2
2014 4
2015 8
2016 2
2017 2
2018 1
2019 5
2020 6
2021 5
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S. Briukhovetska D, et al. Among authors: rothenfusser s. Immunity. 2023 Jan 10;56(1):143-161.e11. doi: 10.1016/j.immuni.2022.12.010. Immunity. 2023. PMID: 36630913 Free PMC article.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S. Lesch S, et al. Among authors: rothenfusser s. Nat Biomed Eng. 2021 Nov;5(11):1246-1260. doi: 10.1038/s41551-021-00737-6. Epub 2021 Jun 3. Nat Biomed Eng. 2021. PMID: 34083764 Free PMC article.
Reply.
Hoffmann F, Endres S, Rothenfusser S. Hoffmann F, et al. Among authors: rothenfusser s. Hepatology. 2016 Mar;63(3):1062-3. doi: 10.1002/hep.27955. Epub 2015 Jul 23. Hepatology. 2016. PMID: 26106015 No abstract available.
Immunotherapy in Tumors.
Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S. Kobold S, et al. Among authors: rothenfusser s. Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Dtsch Arztebl Int. 2015. PMID: 26667979 Free PMC article. Review.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F, Benmebarek MR, Keyl J, Cadilha BL, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S, Jobst J, Müller PJ, Majed L, Seifert M, Klüver AK, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque MP, Heppt MV, Endres S, Klein C, Kobold S. Märkl F, et al. Among authors: rothenfusser s. J Immunother Cancer. 2023 May;11(5):e006436. doi: 10.1136/jitc-2022-006436. J Immunother Cancer. 2023. PMID: 37208128 Free PMC article.
A High-Throughput Yellow Fever Neutralization Assay.
Rasulova M, Vercruysse T, Paulissen J, Coun C, Suin V, Heyndrickx L, Ma J, Geerts K, Timmermans J, Mishra N, Li LH, Kum DB, Coelmont L, Van Gucht S, Karimzadeh H, Thorn-Seshold J, Rothenfußer S, Ariën KK, Neyts J, Dallmeier K, Thibaut HJ. Rasulova M, et al. Among authors: rothenfusser s. Microbiol Spectr. 2022 Jun 29;10(3):e0254821. doi: 10.1128/spectrum.02548-21. Epub 2022 Jun 7. Microbiol Spectr. 2022. PMID: 35670599 Free PMC article.
Strategies to relieve immunosuppression in pancreatic cancer.
Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Schnurr M, et al. Among authors: rothenfusser s. Immunotherapy. 2015;7(4):363-76. doi: 10.2217/imt.15.9. Immunotherapy. 2015. PMID: 25917628 Review.
Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiology.
Nowotny HF, Marchant Seiter T, Ju J, Gottschlich A, Schneider H, Zopp S, Vogel F, Tschaidse L, Auer MK, Lottspeich C, Kobold S, Rothenfusser S, Beuschlein F, Reincke M, Braun L, Reisch N. Nowotny HF, et al. Among authors: rothenfusser s. Front Immunol. 2023 Nov 15;14:1275828. doi: 10.3389/fimmu.2023.1275828. eCollection 2023. Front Immunol. 2023. PMID: 38045693 Free PMC article.
Modes of action of TLR7 agonists in cancer therapy.
Kobold S, Wiedemann G, Rothenfußer S, Endres S. Kobold S, et al. Among authors: rothenfusser s. Immunotherapy. 2014;6(10):1085-95. doi: 10.2217/imt.14.75. Immunotherapy. 2014. PMID: 25428647 Review.
73 results